#USA #New York #Zydus Lifesciences #Oncology Treatment #RK Pharma

Zydus and RK Pharma Join Forces for Innovative Oncology Product

In a significant development in the healthcare sector, Zydus Lifesciences Ltd. has officially partnered with RK Pharma Inc. to introduce a novel oncology supportive care product specifically designed for the United States market. This exclusive licensing and commercialization agreement marks an important milestone for both companies as they aim to enhance patient care through innovative treatment options.

The product in focus is a sterile injectable developed under the 505(b)(2) regulatory pathway, which streamlines the approval process for new drugs that are similar to existing, approved therapies. Zydus will take charge of submitting the New Drug Application (NDA) while RK Pharma will handle the manufacturing and supply of the final product. The NDA submission is projected for 2026, paving the way for this cutting-edge oncology treatment.

Dr. Sharvil Patel, Managing Director of Zydus Lifesciences, expressed excitement over the partnership, stating, “We are delighted to collaborate with RK Pharma to bring this innovative product to patients in the US. This partnership reinforces our commitment to delivering high-quality, affordable medicines and improving patient care.”

This collaboration is particularly noteworthy as the novel product aims to address reducing dosage errors and enhancing compliance among healthcare professionals. By focusing on these critical aspects, the companies hope to provide a safer and more effective solution for patients undergoing oncology treatments.

Dr. Ravishanker Kovi, Founder and Executive Chairman of RK Pharma, underscored the significance of the new product, calling it a testament to RK Pharma’s advanced capabilities in formulation and manufacturing. He noted, “Our collaboration with Zydus, a company with strong regulatory expertise, ensures that this important therapeutic option reaches patients efficiently, reinforcing our shared mission to improve access to high-quality healthcare in the USA.”

According to market research from IQVIA, the product targets a lucrative segment within the U.S. market, with an estimated total addressable market (TAM) of about 6.2 million units as of September 2025. This opportunity not only reflects the demand for innovative oncology treatments but also highlights the potential for Zydus and RK Pharma to make a substantial impact in the healthcare field.

About Zydus Lifesciences

Zydus Lifesciences Ltd. is renowned for its dedication to empowering individuals towards a healthier lifestyle. The company engages in the discovery, development, manufacture, and marketing of a comprehensive array of therapies, particularly in the realm of oncology. Employing over 29,000 personnel globally, including 1,500 scientists involved in research and development, Zydus is proactive in advancing healthcare solutions that genuinely transform lives.

About RK Pharma

Founded in 2018, RK Pharma Inc. has rapidly established itself as a key player in the pharmaceutical landscape. With a focus on developing complex generics and specialized dosage forms such as sterile injectables, RK Pharma operates advanced manufacturing facilities in New York, New Jersey, and India. Their commitment to quality and affordability aims to enhance the quality of life for patients across the healthcare spectrum.

This pioneering collaboration between Zydus Lifesciences and RK Pharma not only promises to innovate oncology supportive care but also sets the stage for further advancements in healthcare through strategic partnerships. As they move towards the NDA submission and eventual product launch, both companies are poised to make a lasting difference in patient care within the United States.